Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
FATE is in the long-term up 745% in 5 years.
Description: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person?s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person?s lifespan. The company?s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dy
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-60.2%||ROE||-126.04%||ROI|
|Current Ratio||6.67||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.3|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||70 K||Cash From Investing Activities||-450 K||Cash From Operating Activities||-6.38 M||Gross Profit|
|Net Profit||-7.88 M||Operating Profit||-7.32 M||Total Assets||44.49 M||Total Current Assets||42.79 M|
|Total Current Liabilities||6.41 M||Total Debt||19.67 M||Total Liabilities||23.24 M||Total Revenue|
|High 52 week||17.59||Low 52 week||7.8||Last close||13.85||Last change||-1.42%|
|RSI||30.71||Average true range||1||Beta||1.29||Volume||25.46 K|
|Simple moving average 20 days||-10.74%||Simple moving average 50 days||-6.2%||Simple moving average 200 days||8.69%|
|Performance Week||-3.55%||Performance Month||-6.29%||Performance Quart||1.76%||Performance Half||41.62%|
|Performance Year||58.29%||Performance Year-to-date||7.95%||Volatility daily||4.18%||Volatility weekly||9.35%|
|Volatility monthly||19.16%||Volatility yearly||66.37%||Relative Volume||139.39%||Average Volume||832.44 K|
|New High||New Low|
2019-09-12 00:53:30 | Fate Therapeutics Announces Pricing of Public Offering of Common Stock
2019-09-11 16:01:00 | Fate Therapeutics Announces Proposed Public Offering of Common Stock
2019-09-10 11:06:20 | Is Fate Therapeutics, Inc.'s NASDAQ:FATE CEO Paid At A Competitive Rate?
2019-09-04 10:02:02 | Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
2019-08-29 08:00:00 | Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference
2019-08-09 11:50:50 | Edited Transcript of FATE earnings conference call or presentation 6-Aug-19 9:00pm GMT
2019-08-07 12:20:40 | Fate Therapeutics, Inc. FATE Q2 2019 Earnings Call Transcript
2019-08-06 18:35:10 | Fate Therapeutics FATE Reports Q2 Loss, Tops Revenue Estimates
2019-08-06 15:00:00 | Fate Therapeutics, Inc. to Host Earnings Call
2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma
2019-07-29 10:34:02 | Will Fate Therapeutics FATE Report Negative Q2 Earnings? What You Should Know
2019-07-08 08:15:00 | Are Natural Killer Cells the Next Big Thing in Immunotherapy?
2019-06-19 18:02:21 | Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc FATE
2019-05-30 16:05:00 | Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference
2019-05-29 08:40:12 | Fate Therapeutics FATE Surges: Stock Moves 6.8% Higher
2019-05-29 07:24:22 | What You Must Know About Fate Therapeutics, Inc.'s NASDAQ:FATE Beta Value
2019-05-08 01:11:15 | Edited Transcript of FATE earnings conference call or presentation 7-May-19 9:00pm GMT
2019-05-07 22:41:16 | Fate Therapeutics, Inc. FATE Q1 2019 Earnings Call Transcript
2019-05-07 18:15:10 | Fate Therapeutics FATE Reports Q1 Loss, Misses Revenue Estimates
2019-05-07 17:07:33 | Fate Therapeutics: 1Q Earnings Snapshot
2019-05-03 11:23:04 | Is Fate Therapeutics Inc FATE A Good Stock To Buy?
2019-04-18 08:01:00 | Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development
2019-04-01 08:01:00 | Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting
2019-03-26 12:12:39 | What Do Analysts Think About Fate Therapeutics, Inc.’s NASDAQ:FATE Earnings Trajectory?
2019-03-06 01:19:38 | Fate Therapeutics Inc FATE Q4 2018 Earnings Conference Call Transcript
2019-03-06 00:33:18 | Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT
2019-03-05 15:00:00 | Fate Therapeutics, Inc. to Host Earnings Call
2019-02-28 10:43:03 | Cronos CRON to Report Q4 Earnings: What's in the Cards?
2019-02-25 10:30:03 | Fate Therapeutics FATE Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2019-02-25 07:30:00 | Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings
2019-02-22 08:00:00 | Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2019-02-07 16:01:00 | Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day
2019-02-06 08:37:00 | Fate Therapeutics stock up 11% after FDA clears IND application
2019-01-22 11:52:10 | Why Fate Therapeutics, Inc.’s NASDAQ:FATE CEO Pay Matters To You